GeoVax Labs, Inc. has entered into definitive agreements for a registered direct offering priced at-the-market under Nasdaq rules, with gross proceeds expected to be approximately $1 million. The biotechnology company will sell 432,902 shares of common stock at $2.31 per share, with closing anticipated around February 17, 2026, subject to customary conditions.
The company will use net proceeds to advance product candidates including research and development, manufacturing, clinical studies, and working capital. This capital infusion comes as GeoVax progresses multiple clinical programs, including its lead COVID-19 vaccine candidate GEO-CM04S1 currently in three Phase 2 trials. The vaccine is being evaluated as a primary vaccine for immunocompromised patients, a booster for chronic lymphocytic leukemia patients, and a more robust booster for healthy patients who previously received mRNA vaccines.
In a concurrent private placement, GeoVax will issue unregistered series A-1 and A-2 warrants to purchase up to 432,902 shares each at $2.31 per share. These warrants become exercisable upon shareholder approval, with A-1 warrants expiring five years after approval and A-2 warrants expiring two years after approval. The company has also agreed to amend existing warrants issued in July 2025, reducing their exercise price from $4.35 to $2.31 per share.
H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The registered direct offering is being made pursuant to a shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC's website at https://www.sec.gov.
Beyond its COVID-19 program, GeoVax's oncology lead clinical program evaluates Gedeptin®, a novel oncolytic solid tumor gene-directed therapy that recently completed a multicenter Phase 1/2 trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to Phase 3 clinical evaluation.
For business and technology leaders monitoring the biotechnology sector, this financing represents a strategic move to advance multiple clinical programs simultaneously. The capital supports development across infectious diseases and oncology, two areas with significant market potential and unmet medical needs. The company's ability to secure funding through a registered direct offering demonstrates investor confidence in its pipeline despite the challenges facing clinical-stage biotech companies.
The offering's structure, including warrant amendments and concurrent private placements, suggests careful financial planning to maximize capital efficiency. For the broader industry, GeoVax's progress highlights continued innovation in vaccine technology and cancer therapies, particularly for immunocompromised populations who may not respond adequately to current vaccines. The company's strong intellectual property portfolio and worldwide rights for its technologies provide additional strategic advantages as it moves toward potential regulatory submissions.
